/wp-content/uploads/logo-300x63.png00Emily Hennes/wp-content/uploads/logo-300x63.pngEmily Hennes2023-07-26 13:50:052023-07-26 13:51:07Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies
/wp-content/uploads/logo-300x63.png00Emily Hennes/wp-content/uploads/logo-300x63.pngEmily Hennes2023-04-11 17:22:132023-04-11 17:22:13Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs
/wp-content/uploads/logo-300x63.png00Emily Hennes/wp-content/uploads/logo-300x63.pngEmily Hennes2023-01-05 17:26:342023-01-05 19:12:40Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
